Study explores adding a low-dose, daily oral chemotherapy for patients with melanoma

UCI Health medical oncologist Poorva Vaidya, MD is currently offering a new clinical trial sponsored by the UC Irvine Anti-Cancer Challenge, and lead by Warren Chow, MD, aimed at tackling a persistent challenge in melanoma care if patients fail first-line immunotherapy.

June 24, 2026

UCI Health

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

#1

Tata Memorial Centre

Mumbai, Maharashtra
Key Differentiators
- Oncology
#2

The University of Texas MD Anderson Cancer Center

Houston, Texas
Key Differentiators
- Oncology
#3

UCI Health

Irvine, California
Key Differentiators
- Oncology
#4

Dana-Farber Cancer Institute

Boston, Massachusetts
Key Differentiators
- Oncology
#5

Eastern Cooperative Oncology Group

New York, New York
Key Differentiators
- Oncology

Study explores adding a low-dose, daily oral chemotherapy for patients with melanoma

Top Institutions in Oncology

Tata Memorial Centre

The University of Texas MD Anderson Cancer Center

UCI Health

Dana-Farber Cancer Institute

Eastern Cooperative Oncology Group

Original Source(s)

Study explores adding a low-dose, daily oral chemotherapy for patients with melanoma

Related Content

Out“FOX”ing cancer: the implications of FOXC2 as a putative predictive biomarker for cancer immunotherapy

Real-world evidence on data quality in precision oncology platforms: insights from the Molecular Twin Research Umbrella protocol

From voice biomarkers to telemedicine screening: developing and evaluating a voice-based AI model for laryngeal lesion detection using the Bridge2AI-Voice dataset